Home > Products > Featured products

Balaglitazone

  Cat. No.:  DC9602   Featured
Chemical Structure
199113-98-9
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Balaglitazone (DRF-2593; NN-2344) is a novel partial agonist of PPAR-γ.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 199113-98-9
Chemical Name: DRF-2593;NN-2344;DRF2593;NN2344;DRF 2593;NN 2344
Synonyms: DRF-2593;NN-2344;DRF2593;NN2344;DRF 2593;NN 2344
SMILES: O=C(N1)SC(CC2=CC=C(OCC(N3C)=NC4=C(C=CC=C4)C3=O)C=C2)C1=O
Formula: C20H17N3O4S
M.Wt: 395.4317
Description: Balaglitazone is a selective partial PPARγ agonist with an EC50 of 1.351 μM for human PPARγ.
In Vivo: Balaglitazone (3 mg/kg, p.o.) shows antihyperglycaemic activity in fully diabetic and insulin resistant db/db mice, and is more potent than the full PPARγ agonist rosiglitazone[1]. Balaglitazone (10 mg/kg, p.o.) suppresses overall glucose, decreases insulin levels, and increases bodyweight in male diet-induced obese rats, and such effects are equal to that of 30 mg/kg pioglitazone[3].
In Vitro: Balaglitazone is a selective partial PPARγ agonist with an EC50 of 1.351 μM[1]. Balaglitazone (5-100 μM) has equal cytotoxicity towards K562 and K562/DOX cells. Balaglitazone decreases doxorubicin cytotoxicity in K562 and K562/DOX cells, with IC50s of 0.117 μM and 0.53 μM, respectively. Balaglitazone reverses multidrug resistance (MDR) in K562/DOX cells. Balaglitazone (25 µM) increases Rh123 accumulation in K562/DOX cells, but does not increases MFI in K562 cells. Balaglitazone downregulates P-gp expression in K562/DOX cells, and such effects are via upregulation of PTEN in K562/DOX cells, and be abolished by PTEN inhibition[2].
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC9602 Balaglitazone Balaglitazone (DRF-2593; NN-2344) is a novel partial agonist of PPAR-γ.
DC7412 R(+)-Etomoxir (sodium salt) A PPARα agonist and an irreversible CPT-1 inhibitor.
DC1034 WY14643 (Pirinixic Acid) WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with ED50 of 1.5 μM.
DC10700 Seladelpar Seladelpar is a selective peroxisome proliferator-activated receptor (SPPAR) -δ receptor agonist.
DC12034 MA-0204 MA-0204 is a potent, selective PPARδ modulator with good pharmacokinetic properties.
DC2079 GW-9662 GW9662 is a selective PPAR antagonist, inhibiting PPARγ, PPARα and PPARδ with IC50 of 3.3 nM, 32 nM and 2 μM, respectively.
DC4233 GW501516 GW501516 is the most selective and potent PPARβ (EC50=1.1nM) agonist that has been demonstrated to be 1,000-fold more selective in comparison to existing subtypes.
DC9904 GW0742 GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
DC2078 GW-7647 GW 7647 is a potent PPARα agonist with 200-fold selectivity over PPARγ and PPARδ.
DC1035 GSK3787 GSK3787 is as a potent and selective antagonist of PPARδ with pIC50 of 6.6.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia